Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D231/16—Halogen atoms or nitro radicals

Definitions

• This invention relates to novel pyrazolo[1,5-c]quinazoline derivatives, their preparation and compositions containing them.
• the invention relates to novel pyrazolo[1,5-c]quinazoline compounds having the general formula I ##STR2## wherein R represents a hydrogen atom, a C 1-4 alkyl group or an acyl group,
• R 1 represents a hydrogen atom, a C 1-12 alkyl group, a C 3-8 cycloalkyl group, a C 2-4 alkenyl group, an aralkyl group, wherein the alkyl group has 1 to 4 carbon atoms, a phenylalkyl group, wherein the alkenyl group has 2 to 4 carbon atoms, furthermore a carboxy group or a phenyl group optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, C 1-4 alkoxy, nitro or di(C 1-4 alkyl)amino groups, or
• R and R 1 may form together a valence bond
• R 2 represents a hydrogen atom, a C 1-4 alkyl or a phenyl group, or
• R 1 and R 2 may form together a C 2-7 alkylene group
• R 3 represents a nitro group, an amino group, an alkylamino group, a dialkylamino group, wherein the alkyl groups have 1 to 4 carbon atoms, an alkylideneimino group, wherein the alkylidene group has 1 to 4 carbon atoms, a benzylideneimino group or an acylamino group,
• novel compounds can be employed primarily as analgesic agents.
• a C 1-4 alkyl group is a methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, tert.-butyl or isobutyl group.
• An acyl group is preferably an alkanoyl group, such as formyl, acetyl, propionyl, etc., an aroyl group, such as benzoyl, substituted benzoyl, etc. or an aralkanoyl group, such as phenylacetyl etc.
• a C 1-12 alkyl group means a linear or branched chain alkyl group, such as a methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, tert.-butyl, isobutyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl or dodecyl group.
• a C 3-8 cycloalkyl group is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl group, especially a cyclohexyl group.
• a C 2-4 alkenyl group is preferably a propenyl or butenyl group.
• An aralkyl group is preferably a benzyl or phenylethyl group.
• a phenylalkenyl group is preferably a phenylpropenyl or phenylbutenyl group, especially a styryl group.
• a substituted phenyl group is preferably a nitrophenyl, methoxyphenyl, hydroxyphenyl, halogenphenyl, such as chlorophenyl or bromophenyl, N,N-dimethylaminophenyl or N,N-diethylaminophenyl group.
• R 1 and R 2 form together a C 2-7 alkylene group
• a 3- to 8-membered alicyclic ring such as cyclopropane, cyclopentane, cyclohexane, cycloheptane or cyclooctane ring is produced.
• the alkylideneimino group is an ethylideneimino, isopropylideneimino or butylideneimino group, especially an isopropylideneimino group.
• the pharmaceutically acceptable acid addition salt can be an inorganic acid addition salt, such as sulfate, hydrochloride, hydrobromide, etc. or an organic acid additon salt, such as acetate, fumarate, maleate, citrate, lactate, etc.
• a subclass of the compounds of the invention consists of the nitropyrazolo[1,5-c]quinazoline derivatives of the general formula Ia ##STR3## wherein R 2 is as stated above, and the pharmaceutically acceptable acid addition salts thereof.
• R 2 represents a hydrogen atom or a C 1-4 alkyl group.
• a further subclass of the compounds of the invention consists of the aminopyrazolo[1,5-c]quinazoline derivatives of the general formula Ib ##STR4## wherein R 2 is as stated above, R 4 represents a hydrogen atom, a C 1-4 alkyl group or an acyl group, R 5 represents a hydrogen atom or a C 1-4 alkyl group or R 4 and R 5 form together a C 1-4 alkylidene group, and the pharmaceutically acceptable acid addition salts thereof.
• R 2 represents a hydrogen atom or a C 1-4 alkyl group
• R 5 stands for a hydrogen atom
• R 4 is a C 1-4 alkanoyl group.
• the compounds of the invention include also the nitropyrazolo[1,5-c]quinazoline derivatives of the general formula Ic ##STR5## wherein R 1 and R 2 are as stated above, and the pharmaceutically acceptable acid addition salts thereof.
• R 1 and R 2 each represents a hydrogen atom.
• a still further subclass of the compounds of the invention includes the nitropyrazolo[1,5-c]quinazoline derivatives of the general formula Id ##STR6## wherein R 1 and R 2 are as stated above, R 6 represents a C 1-4 alkyl group or an acyl group, and the pharmaceutically acceptable acid addition salts thereof.
• R 1 represents a C 1-4 alkyl group
• R 2 stands for a hydrogen atom or a C 1-4 alkyl group
• R 6 represents a a C 1-4 alkanoyl group, such as an acetyl group.
• An additional subclass of the compounds of the invention includes the aminopyrazolo[1,5-c]quinazoline derivatives of the general formula If ##STR7## wherein R, R 1 , R 2 , R 4 and R 5 are as stated above, and the pharmaceutically acceptable acid addition salts thereof.
• R represents a hydrogen atom or a C 1-4 alkanoyl group
• R 1 and R 2 each stands for a C 1-4 alkyl group
• R 5 is a hydrogen atom
• R 4 represents a C 1-4 alkanoyl group.
• Preferred pyrazolo[1,5-c]quinazoline derivatives of the invention are as follows:
• Alk represents a C 1-4 alkyl group and R 2 is as stated above, or with a carboxylic halogenide of the general formula IV ##STR9## wherein R 2 is as stated above and Hal represents a halogen atom, or with a carboxylic anhydride of the general formula V
• R 2 is as stated above;
• R 2 is as stated above;
• any compound of the general formula I is converted with an inorganic or organic acid into its acid addition salt, or the compound of the general formula I is liberated from its acid addition salt with a base.
• the above reaction can be performed in the presence of a solvent, such as an aromatic hydrocarbon, e.g. benzene, toluene or xylene, too.
• a solvent such as an aromatic hydrocarbon, e.g. benzene, toluene or xylene, too.
• the 5-(o-aminophenyl)-4-nitropyrazole is reacted with a carboxylic halogenide of the general formula IV preferably in the presence of an acid binding agent, such as pyridine or triethylamine.
• the acid binding agent can be simultaneously used as a solvent or diluent, too.
• a further possibility is to perform the reaction in the presence of an inert solvent, preferably an aromatic hydrocarbon.
• the reaction temperature is from 0° C. to the boiling point of the solvent used.
• a carboxylic halogenide of the general formula IV the carboxylic chloride or bromide are preferred.
• the starting compound of the formula II is reacted with a carboxylic anhydride of the general formula V
• the latter compound is employed in an equimolar quantity or in an excess.
• the reaction temperature is from 20° to 200° C., especially at the boiling point of the carboxylic acid anhydride used.
• the starting compound of the formula II is reacted with an aldehyde of the general formula VI or a ketone of the general formula VII preferably in the presence of a solvent, such as water, a polar organic solvent, e.g. methanol, ethanol, formic acid, acetic acid, etc. Mixtures of polar solvents can be used, too.
• a solvent such as water, a polar organic solvent, e.g. methanol, ethanol, formic acid, acetic acid, etc.
• reaction components of the general formula VI or VII can be used in excess. In this case they have the function of the solvent, too.
• the reaction temperature is, in general, from 0° C. to the boiling point of the solvent used.
• the reaction rate can be enhanced by employing a catalyst, such as acids.
• the nitropyrazolo[1,5-c]quinazolines of the general formulae Ia and Ie are preferably reduced by catalytic hydrogenation in an inert solvent such as an alkanol.
• the catalyst may be Raney nickel, palladium/carbon or platinum dioxide.
• the compounds of the general formulae Ia and Ie may be reduced by any conventional method suitable for the reduction of nitro compounds.
• the active acylating derivative of a carboxylic acid is a compound suitable for the acetylation of the nitrogen atom, such as a carboxylic halogenide, e.g. chloride or bromide, a carboxylic ester, an activated carboxylic ester, a carboxylic anhydride or a mixed anhydride.
• the starting 5-(o-aminophenyl)-4-nitropyrazole of the formula II can be prepared from 4-chloro-3-nitroquinoline by adapting Alberi's method [Gazz. chim. ital., 87, 772 (1957)].
• novel compounds of the general formula I have shown biological activities in several pharmacological tests.
• the novel compounds exert valuable analgesic effects, furthermore, inhibit the secretion of gastric acid and possess antiperistaltic effects.
• the analgesic activity was studied by means of the acetic acid writhing test on mice. After the intraperitoneal administration of 0.4 ml of 0.5 percent acetic acid, the writhing responses were counted between the 5 and 10 minutes. The writhing number was calculated as the percentage of the control value.
• the compounds tested were orally administered to the animals 1 hour prior to the treatment with acetic acid.
• the control group was treated orally with a carrier without active substance.
• Table II The results obtained are summarized in Table II in which the values of ED 50 and therapeutic index of the test compounds as well as the reference substances are given. Paracetamole [p-hydroxyacetanilide] and phenylbutazon [4-butyl-1,2-diphenylpyrazolidine-3,5-dione] were used as reference substance.
• the antiperistaltic effect of the compounds of the invention was examined on groups of mice consisting of 10 animals. Each dosis of the compound to be tested was administered to one group, orally, 60 minutes prior to the administration of a 10 percent carbon suspension. 20 minutes after the administration of the carbon suspension, the animals were sacrificed and the length of the entire small intestine as well as that of the small intestine filled with carbon were determined.
• the reference substance used was papaverine [1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline]. The results obtained are summarized in Table IV.
• the compounds of the general formula I as well as the acid addition salts thereof can be employed as active substances in pharmaceutical compositions having primarily analgesic effect.
• the pharmaceutical products are prepared by admixing the novel compounds of the general formula I or their acid addition salts with carriers usable in the pharmaceutical industry and transforming the mixture obtained into pharmaceutical products.
• a typical dose for adult patients is 1 to 1000 mg/kg, especially 2 to 500 mg/kg.
• Preferable pharmaceutical products for oral administration such as tablets, capsules, coated tablets, solutions, suspensions, etc. or for parenteral administration, such as sterile solutions or suspensions are prepared.
• Carriers in the solid pharmaceutical products may be binding agents such as gelatin, sorbitol, polyvinylpyrrolidone, filling agents, such as lactose, sugar, starch, calcium phosphate, auxiliary agents for tabletting, such as magnesium stearate, polyethyleneglycol, silica, wetting agents, such as sodium laurylsulfate, etc.
• binding agents such as gelatin, sorbitol, polyvinylpyrrolidone
• filling agents such as lactose, sugar, starch, calcium phosphate
• auxiliary agents for tabletting such as magnesium stearate, polyethyleneglycol, silica
• wetting agents such as sodium laurylsulfate, etc.
• Carriers in the liquid pharmaceutical products may be suspending agents, such as sorbitol, sugar solution, gelatin, carboxymethylcellulose, emulsifying agents, such as sorbitan monooleate, solvents, such as oils, glycine, propyleneglycol, ethanol, preservatives, such as methyl-p-hydroxybenzoate, propyl-p-hydroxybenzoate, etc.
• suspending agents such as sorbitol, sugar solution, gelatin, carboxymethylcellulose
• emulsifying agents such as sorbitan monooleate
• solvents such as oils, glycine, propyleneglycol, ethanol
• preservatives such as methyl-p-hydroxybenzoate, propyl-p-hydroxybenzoate, etc.
• the pharmaceutical products may contain known flavouring and colouring agents, too.
• Example 5 is repeated with the exception that, instead of acetic anhydride, propionic anhydride is employed. 1-Propionylaminopyrazolo[1,5-c]quinazoline is obtained. M.p.: 202°-204° C.
• Example 9 is repeated with the exception that, instead of acetone, diethylketone is used. 1-Nitro-5,5-diethyl-5,6-dihydropyrazolo[1,5-c]quinazoline is obtained. M.p.: 132°-134° C. Yield: 97%.
• Example 11 is repeated with the exception that, instead of acetaldehyde, 40 percent aqueous formaldehyde is employed. 1-Nitro-5,6-dihydropyrazolo[1,5-c]quinazoline is obtained. M.p.: 156°-157° C. Yield: 83%.
• Example 11 is repeated with the exception that, instead of acetaldehyde, benzaldehyde is used.
• 1-Nitro-5-phenyl-5,6-dihydropyrazolo[1,5-c]quinazoline is obtained. M.p.: 157°-158° C. Yield: 82.5%.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=10995850

Family Applications (1)

Country Status (17)

Cited By (4)

Families Citing this family (1)

Citations (5)

Family Cites Families (2)

• 1979
  • 1979-05-18 HU HU79EE2663A patent/HU178523B/hu not_active IP Right Cessation
• 1980
  • 1980-05-09 BE BE1/9814A patent/BE883204A/fr not_active IP Right Cessation
  • 1980-05-12 FR FR8010562A patent/FR2456744A1/fr active Granted
  • 1980-05-13 GB GB8015781A patent/GB2051054B/en not_active Expired
  • 1980-05-16 US US06/150,349 patent/US4303660A/en not_active Expired - Lifetime
  • 1980-05-16 AT AT0262580A patent/AT375941B/de not_active IP Right Cessation
  • 1980-05-16 CS CS803407A patent/CS241026B2/cs unknown
  • 1980-05-16 JP JP6420580A patent/JPS55154974A/ja active Granted
  • 1980-05-16 AU AU58485/80A patent/AU528013B2/en not_active Ceased
  • 1980-05-16 SU SU802924054A patent/SU978731A3/ru active
  • 1980-05-16 CH CH382280A patent/CH646170A5/de not_active IP Right Cessation
  • 1980-05-16 DD DD80221164A patent/DD150897A5/de not_active IP Right Cessation
  • 1980-05-16 GR GR61970A patent/GR68462B/el unknown
  • 1980-05-16 IT IT22111/80A patent/IT1149882B/it active
  • 1980-05-16 NL NL8002853A patent/NL8002853A/nl not_active Application Discontinuation
  • 1980-05-19 DE DE19803019019 patent/DE3019019A1/de active Granted
  • 1980-05-19 ES ES491608A patent/ES491608A0/es active Granted
• 1981
  • 1981-05-26 SU SU813287153A patent/SU1017171A3/ru active
  • 1981-05-26 SU SU813287448A patent/SU1015828A3/ru active

Patent Citations (5)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events